



Two Florida Companies Partner in the Fight Against Cancer using ROA to Define the Higher Order Structure of PTB, a Unique Monoclonal Antibody

Vero Beach, Florida, (April 5, 2022) – Nascent Biotech, developer of Pritumumab (PTB), a monoclonal antibody shown promise in the treatment of brain cancer, has partnered with BioTools Inc (Jupiter, FL) to clearly define PTB’s higher order molecular structure (HOS).

Nascent is exploring the potential of modifying the antibody to enhance its effectiveness and to broaden its therapeutic application. BioTools’ groundbreaking ROA laser-based technology provides detailed and complete structural characterization at all stages of development including formulation and stability. ROA spectrum generates a structural snapshot and unique signature for each product and each modification.

PTB is a natural human IgG1 antibody isolated from a patient with cervical carcinoma. It is a protein molecule comprised of multiple amino acid units linked together into a chain which can then fold into various configurations. Both the folding (“secondary structure”) and the more extensive, 3-dimensional results (“tertiary structure”) have dramatic impact on the molecule’s pharmaceutical effectiveness.

BioTools has developed the first commercially available Raman/ROA spectrometer. This 1-2 punch provides a powerful probe to characterize those higher order structures, especially illuminating the effects of the local environment including hydration and side chain positioning or “conformation.” Raman/ROA can be used for HOS determinations in a wide range of bio-based therapeutics including monoclonal antibodies (mAbs), nucleic acids, sugars, and viruses as well as other products produced from living organisms including vaccines, blood or blood components, or specialized proteins.

“BioTools is known worldwide for their knowledge and expertise in the field of Raman, ROA, and biologic FTIR. We are very pleased to have had an opportunity to work with their scientists to deliver this refined capability for our monoclonal antibody (mAb) development platform.” – Sean Carrick, CEO, Nascent Biotech Inc.

“Nascent’s mAb PTB is an ideal match for our instrumentation as well as for our vision of expanding Raman/ROA+FTIR to more widespread, routine use in BioPharma research labs. This suite of techniques, coupled with the accompanying BioTools’ databases and software, have powerful application to the characterization of higher order structures for many therapeutics.”–BioTools, President & Co-Founder, Dr. Rina Dukor

ROA has been published in hundreds of scientific papers. It is currently employed by several major pharmaceutical companies worldwide and is available as a contract service through BioTools.

END

About BioTools

BioTools is a life sciences tools company that revolutionized characterization technology for the most important therapeutics of our time - chiral small molecules and biologics. The breakthrough analytical techniques developed by the company provide molecular structure information which governs safety and efficacy – analyzed in a fraction of a time compared to traditional methodology.

BioTools product offerings include instrumentation, specialized CRO services, and unique software and accessories. The products are used globally by most of the world's top 100 pharmaceutical companies, renowned academic institutions, and government laboratories, including the US Food & Drug Administration (FDA).

Founded in 2000, BioTools has R&D, sales, customer support, contract research lab and manufacturing facilities in Jupiter, Florida, and two international divisions, BioTools Europe, headquartered in the United Kingdom, and BioTools China, headquartered in Dalian. BioTools' co-founders and products have been recognized by numerous International Awards, including the R&D 100 Top Innovation Award.

For more information, visit <https://biotools.us/> or contact us at info@biotools.us.

Follow us on [LinkedIn](#) and [Twitter](#)

About Nascent Biotech

Nascent Biotech, Inc. (OTCQB: NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies to be used in the treatment of various cancers helping millions of people worldwide. Its products are not yet commercially available. The Company's lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that is being studied in Phase I clinical trials for the treatment of Brain Cancer at Sharp Healthcare and Hoag Presbyterian Hospital.

For further information, contact:

Sean Carrick, President | CEO, Nascent Biotech

E: sean.carrick@nascentbiotech.com

W: www.nascentbiotech.com

P: 772.713.0541

Rina Dukor, President & Co-Founder, BioTools, Inc.

E: rkdukor@biotools.us

W: www.biotools.us

P: 561.625.0133